AAIC 2025 Abstract
Plasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participants
Trial in peopleInterventions
Abstract
Background: Participants with Alzheimer's disease (AD) treated with sigma‐2 receptor (S2R) modulator zervimesine (CT1812) exhibited 39% slowing of cognitive decline (ADAS‐Cog11) compared to placebo in the mITT cohort of the SHINE trial (NCT03507790, COG0201).
